PRS-344 + ONC0055

PRS-344 + ONC0055 is an investigational combination therapy for solid tumors. PRS-344 (also known as S095012) is a bispecific fusion protein consisting of a PD-L1–targeting antibody and 4-1BB–targeting Anticalin proteins. Mechanistically, PRS-344/S095012 blocks the PD-1/PD-L1 immune checkpoint and simultaneously provides tumor-localized costimulation of 4-1BB (a T cell costimulatory receptor), thus enhancing antitumor immunity by potentiating T cell activation and cytokine release in a manner dependent on both PD-L1 expression and T cell receptor (TCR) engagement[3][4][9][13][18][22]. ONC0055, based on available information, is associated with Rapafusyn Pharmaceuticals and is described as a non-degrading molecular glue for solid tumors, but its detailed mechanism and structure are unclear[2]. The combination is intended to synergistically boost antitumor immunity by dual targeting, but no detailed data on ONC0055’s molecular target, mechanism, or published clinical data for the combination exists.

Other names

PRS-344/S095012 + ONC0055